Trademark: 78355970
Word
EPIGENESIS PHARMACEUTICALS
Status
Dead
Status Code
606
Status Date
Monday, October 27, 2008
Serial Number
78355970
Mark Type
3000
Filing Date
Thursday, January 22, 2004
Published for Opposition
Tuesday, July 5, 2005
Abandoned Date
Monday, October 27, 2008

Trademark Owner History
EPIGENESIS PHARMACEUTICALS LLC - Owner At Publication
EPIGENESIS Pharmaceuticals, Inc. - Original Applicant

Classifications
5 Medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
Color is not claimed as a feature of the mark.
PHARMACEUTICALS

Trademark Events
Oct 27, 2008
Abandonment Notice Mailed - No Use Statement Filed
Oct 27, 2008
Abandonment - No Use Statement Filed
Apr 4, 2008
Extension 5 Granted
Mar 14, 2008
Extension 5 Filed
Mar 14, 2008
Teas Extension Received
Sep 26, 2007
Extension 4 Granted
Sep 13, 2007
Extension 4 Filed
Sep 13, 2007
Teas Extension Received
Jun 28, 2007
Extension 3 Granted
Mar 20, 2007
Extension 3 Filed
Mar 20, 2007
Teas Extension Received
Oct 24, 2006
Extension 2 Granted
Sep 22, 2006
Extension 2 Filed
Sep 22, 2006
Teas Extension Received
Apr 28, 2006
Extension 1 Granted
Mar 24, 2006
Extension 1 Filed
Mar 24, 2006
Teas Extension Received
Sep 27, 2005
Noa Mailed - Sou Required From Applicant
Jul 5, 2005
Published For Opposition
Jun 15, 2005
Notice Of Publication
Mar 28, 2005
Law Office Publication Review Completed
Mar 25, 2005
Assigned To Lie
Mar 18, 2005
Approved For Pub - Principal Register
Mar 17, 2005
Amendment From Applicant Entered
Jan 31, 2005
Correspondence Received In Law Office
Jan 31, 2005
Paper Received
Oct 5, 2004
Teas Change Of Correspondence Received
Aug 21, 2004
Non-Final Action E-Mailed
Aug 12, 2004
Assigned To Examiner
Jul 20, 2004
Teas Voluntary Amendment Received
Jul 16, 2004
Paper Received
Feb 2, 2004
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24